Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
Cost of Revenue
Halozyme Therapeutics Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Cost of Revenue
-$185.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
-33%
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
See Also
What is Halozyme Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-185.5m
USD
Based on the financial report for Mar 31, 2024, Halozyme Therapeutics Inc's Cost of Revenue amounts to -185.5m USD.
What is Halozyme Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-33%
Over the last year, the Cost of Revenue growth was -17%. The average annual Cost of Revenue growth rates for Halozyme Therapeutics Inc have been -49% over the past three years , -74% over the past five years , and -33% over the past ten years .